SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 3 — Focused Visit (Follow-up) — Wilma Mankiller

PatientWilma Mankiller
Date of birth1991-11-18
IdentifiersMRN HR-ML052-SYN; SSN (made up) 000-52-4183
Document date2026-05-04
AuthorRena Hawkfeather-Lindqvist, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Six-week review on pyridostigmine and prednisone. [S]

History of Present Illness

Ms. Mankiller returns six weeks after starting prednisone, which reached 40 mg each morning two weeks ago. She had no worsening as the dose rose. Her eyelids droop only late in the evening now, double vision is rare, and she can brush her hair and finish meals without resting. She sleeps less well and feels hungrier, and has gained about 2 kg. She has had no infections. The screening tests drawn at the last visit were normal: TPMT activity normal, hepatitis B surface antigen and core antibody negative with immunity from vaccination, and the tuberculosis blood test negative. She saw the thoracic surgeon two weeks ago, and a robotic thymectomy is planned in five weeks. Her home blood pressure readings average 118/76. She drinks about 2.5 liters of water a day. [S]

ElementDetail
Prednisone40 mg each morning for two weeks; no early worsening
StrengthMG-ADL 3, from 7
ScreeningTPMT normal; hepatitis B and tuberculosis screens negative
ThymectomyRobotic thymectomy planned in five weeks

Review of Systems

SystemResultFinding
EyesPositiveMild ptosis late in the evening; double vision rare
ConstitutionalPositiveWeight up about 2 kg; hungrier on prednisone
PsychiatricPositiveSleeps less well on prednisone; mood steady; PHQ-2 score 1
RespiratoryNegativeNo breathlessness; cough strong
IntegumentaryNegativeNo infections or skin problems

5 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Pyridostigmine bromide 30 mg oral tablet, one tablet three times daily with meals as a trial; take 30 to 45 minutes before eatingOne tablet three times dailyOral route2026-03-09 to 2026-03-23completedS
Pyridostigmine bromide 60 mg oral tablet, one tablet four times daily while awake, 30 to 45 minutes before mealsOne tablet four times daily while awakeOral route2026-03-23 to 2026-10-12completedS
Prednisone 10 mg oral tablet, 10 mg each morning, rising by 10 mg each week to 40 mg each morning, then held at 40 mgOnce each morning; dose as directedOral route2026-03-23 to 2026-07-13completedS
Azathioprine 50 mg oral tablet, one tablet daily for two weeks, then two tablets daily, then three tablets (150 mg, about 2.3 mg/kg) dailyOnce daily; dose as directedOral route2026-05-04activeS
Calcium carbonate 1250 mg (500 mg elemental calcium) oral tablet, one tablet daily with foodOne tablet daily with foodOral route2026-03-23activeS
Cholecalciferol (vitamin D3) 1000 units (0.025 mg) oral tablet, one tablet dailyOne tablet dailyOral route2026-03-23activeS
Sulfamethoxazole 800 mg / trimethoprim 160 mg oral tablet, one tablet three times a week, while prednisone is 20 mg or more with azathioprineOne tablet on Monday, Wednesday and FridayOral route2026-05-04 to 2026-10-05completedS
Acetaminophen 500 mg oral tablet, one or two tablets up to three times daily as needed for leg painOne or two tablets up to three times daily as neededOral route2025-09-15activeS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
2026-05-04Body height163cmS
2026-05-04Body weight63.9kgS
2026-05-04Body mass index (BMI) [Ratio]24.1kg/m2S
2026-05-04Systolic blood pressure128mm[Hg]S
2026-05-04Diastolic blood pressure82mm[Hg]S
2026-05-04Heart rate80/minS
2026-05-04Respiratory rate16/minS
2026-05-04Body temperature36.6CelS
2026-05-04Oxygen saturation in Arterial blood by Pulse oximetry98%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
2026-05-04Hemoglobin [Mass/volume] in Blood13.2g/dL11.6-15 g/dLNormalS
2026-05-04Leukocytes [#/volume] in Blood by Automated count10.410*3/uL4-11 10*3/uLNormalS
2026-05-04Platelets [#/volume] in Blood by Automated count28410*3/uL150-400 10*3/uLNormalS
2026-05-04Potassium [Moles/volume] in Serum or Plasma4mmol/L3.5-5.1 mmol/LNormalS
2026-05-04Glucose [Mass/volume] in Serum or Plasma104mg/dL70-99 mg/dLHighS
2026-05-04Creatinine [Mass/volume] in Serum or Plasma0.76mg/dL0.59-1.04 mg/dLNormalS
2026-05-04Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M105mL/min/{1.73_m2}>=60 mL/min/1.73 m²NormalS
2026-05-04Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma20U/L7-45 U/LNormalS
2026-05-04Forced vital capacity [Volume] Respiratory system3.48LLower limit of normal about 2.9 L for her age, sex and heightNormalS
2026-05-04DXA Femur [Z-score] Bone density-0.4{Z-score}Above -2.0 is within the expected range for ageNormalS
2026-05-04DXA Lumbar spine [Z-score] Bone density-0.7{Z-score}Above -2.0 is within the expected range for ageNormalS
2026-05-04Patient Health Questionnaire 2 item (PHQ-2) total score [Reported]1{score}S

Physical Exam

Vital signs recorded on 2026-05-04; see the Vital Signs section. [S]

SystemFinding
GeneralWell; blood pressure 128/82 mm Hg; weight 63.9 kg
EyesNo ptosis after one minute of upgaze; eye movements full
NeurologicalNeck flexion 5 of 5; arm abduction held for 90 seconds; counts to 50 without a nasal voice
RespiratoryFVC 3.48 L

Problems

ProblemClinical statusVerificationCodeProvenance
Drooping eyelids and double vision for six weeks, worse in the evening, with fatigable weakness of the arms and neck, tiring when chewing and a nasal voice after long talks; a disorder of the neuromuscular junction suspectedresolvedconfirmed H53.2S — Synthetic presenting problem, resolved at the second visit when antibodies and nerve testing established myasthenia gravis.
Generalized myasthenia gravis, acetylcholine receptor antibody positive, MGFA class IIa, without thymoma; synthetic modern detail linked to her documented myasthenia gravis of 1980activeconfirmed G70.00S — Synthetic antibody level, electrodiagnosis, class and treatment; the diagnosis less than a year after the crash, and recovery with Cherokee medicine people, surgery and drug therapy, are documented (D).
Autosomal dominant polycystic kidney disease (hereditary, as she has described it), with normal kidney function; to be stagedactiveconfirmed Q61.2S — The hereditary polycystic kidney disease is documented (D) from her later public account; its detection before the index date, and every value, are synthetic.
Recovery from major trauma in a head-on car crash last year: fractures of both legs, ribs and face, with many operations; walks independently, with a cane on rough groundactiveconfirmed Z87.81S — The crash, the operations and the injuries are documented (D); the current function is synthetic.
Long-term glucocorticoid therapy for myasthenia gravis, with monitoring of glucose, blood pressure, weight, bone health, mood, sleep, eyes and infectionactiveconfirmed Z79.52S — Synthetic treatment plan.
Azathioprine as steroid-sparing therapy, with blood count and liver test monitoringactiveconfirmed Z79.624S — Synthetic treatment plan.

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
SurveyMG-ADL scoreEvery visitCompleted today3, down from 7
ImagingForced vital capacityEvery visit while on dose changesCompleted today3.48 L, up from 3.25
ExaminationMyasthenic crisis warning signs and early steroid worseningEvery visitCompleted todayNone during the rise to 40 mg
LaboratoryBlood count before azathioprineBaseline, then every one to two weeks for two monthsCompleted todayHemoglobin 13.2 g/dL; white cells 10.4 on prednisone; platelets 284
LaboratoryChemistry: potassium, glucose, creatinine, eGFR and ALTBaseline before azathioprine and periodically on glucocorticoidsCompleted todayPotassium 4.0 mmol/L; glucose 104 mg/dL non-fasting; creatinine 0.76 mg/dL; eGFR 105; ALT 20 U/L
LaboratoryTPMT, hepatitis B and tuberculosis screeningBefore azathioprineCompleted todayTPMT activity normal; hepatitis B surface antigen and core antibody negative, surface antibody positive; interferon-gamma release assay negative
ImagingBone density (DXA)Soon after starting glucocorticoids expected to last more than three monthsCompleted todayFemoral neck Z-score -0.4; lumbar spine Z-score -0.7
ExaminationBlood pressure and weightEvery visitCompleted today128/82 mm Hg in clinic; home average 118/76; weight up 2.3 kg
ExaminationEye examination on glucocorticoidsYearlyDueWithin the year, at the Cherokee Nation eye clinic
Medication safetyPneumocystis prophylaxisWhile prednisone is 20 mg or more with a second immunosuppressantCompleted todayTrimethoprim-sulfamethoxazole three times a week from today; potassium will be watched
Medication safetyMedicines that can worsen myasthenia gravisWith every new prescriptionCompleted todaySurgical and anesthesia teams told; the list sent with the thymectomy referral
SurveyDepression screen (PHQ-2) and sleepAt intervalsCompleted todayPHQ-2 score 1; sleep shorter on prednisone
ReferralThoracic surgeryOnceCompleted todaySeen two weeks ago; robotic thymectomy planned in five weeks
Self-managementHome blood pressure and water intakeEvery visitCompleted todayHome readings about 118/76; water about 2.5 liters a day

Goal progress:

Guideline basis: Narayanaswami P, et al. International Consensus Guidance for Management of Myasthenia Gravis: 2020 Update. Neurology 2021;96(3):114-122 (2020); Sanders DB, et al. International consensus guidance for management of myasthenia gravis: Executive summary. Neurology 2016;87(4):419-425 (2016); KDIGO 2025 Clinical Practice Guideline for the Evaluation, Management, and Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD). Kidney Int 2025;107(2S):S1-S239 (2025); Humphrey MB, et al. 2022 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis. Arthritis Rheumatol 2023;75(12):2088-2102 (2022)

Follow-up: Blood count and liver tests at two, four and six weeks at the Cherokee Nation clinic near her home. Thymectomy in five weeks. Review here five weeks after surgery. Next scheduled visit 2026-07-13: review five weeks after thymectomy: recovery, pathology, azathioprine monitoring, the prednisone taper, and kidney care. [S]